The neurokinin 1 receptor: a potential new target for anti-platelet therapy?

Sarah Jones, Jonathan M. Gibbins

    Research output: Contribution to journalArticlepeer-review


    The important role of platelets in the development of arterial thrombosis and cardiovascular disease is well established. Current treatments for arterial thrombosis include anti-platelet agents such as aspirin, thienopyridines and glycoprotein IIb-IIIa inhibitors. Despite these drugs being effective there remains a substantial unmet clinical demand for more effective therapeutic approaches, which may reflect the existence of alternative underlying regulatory mechanisms to those already targeted. Recent publications have demonstrated a key role for tachykinins in the positive feedback regulation of platelet aggregation and thrombus formation. The pro-thrombotic effects of tachykinins on platelets are mediated through the neurokinin 1 receptor, which may therefore offer a novel therapeutic drug target in the prevention and the treatment of arterial thrombosis. © 2008 Elsevier Ltd. All rights reserved.
    Original languageEnglish
    Pages (from-to)114-119
    Number of pages5
    JournalCurrent opinion in pharmacology
    Issue number2
    Publication statusPublished - Apr 2008


    • Animals
    • Blood Platelets/drug effects/metabolism
    • Drug Delivery Systems
    • Humans
    • Platelet Aggregation Inhibitors/*pharmacology
    • Receptors, Neurokinin-1/*drug effects/metabolism
    • Tachykinins/drug effects/metabolism
    • Thrombosis/*drug therapy/physiopathology


    Dive into the research topics of 'The neurokinin 1 receptor: a potential new target for anti-platelet therapy?'. Together they form a unique fingerprint.

    Cite this